Exelixis (NASDAQ: EXEL)
Key Data Points
Exelixis Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Exelixis Company Info
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
News & Analysis
Why Exelixis Stock Trounced the Market on Thursday
Exelixis Posts 63.7% Profit Surge
Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive pressures and regulatory challenges remain.
Exelixis' Sales, Earnings Surge in Q3
The drugmaker reported robust results driven by its cabozantinib franchise.
1 No-Brainer Stock to Buy With $40
The midcap biotech just became an even better buy.
2 Stocks Under $30 to Buy and Hold
You don't need to be a millionaire to get started. Investing on a budget can work, too.
Is Exelixis Stock a Buy Now?
There is one key reason to consider the stock.
2 Top Biotech Stocks Defying the Bear Market
The best may be yet to come for these companies.
The Top Healthcare Stocks to Buy With $100
Both stocks have outperformed the broader market in the last 12 months.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.